About
Approach
Pipeline
Publications
- Publications
- Data Presentations
For Patients
Join Us
Investors & Media
Contact Us

Investors & Media|
- Overview|
- Corporate Presentation|
- News|
- Events|
- Stock Quote and Chart|
  - Historical Data|
- Analyst Coverage|
- SEC Filings|
- Governance|
- Info|
Contact Us|

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Back to Careers

Stay Connected

Email Alerts Contacts RSS News Feed

©2024 Rezolute, Inc.

Explore

About
Approach
Pipeline
Publications
For Patients
Join Us
Investors & Media
Contact Us

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

Terms of Use
Privacy Policy

MENU

About
Approach
Pipeline
Publications
- Publications
- Data Presentations
For Patients
Join Us
Investors & Media
Contact Us